Gastric Cancer Drug Zolbetuximab Drives Widespread Albumin Loss in Real-World Patients
A real-world study finds that every patient treated with zolbetuximab for CLDN18.2-positive advanced gastric cancer developed hypoalbuminemia, with prior total ...
